Author: Barb Richard

NervGen Pharma Grants Stock Options

Vancouver, Canada. February 23, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to […]

NervGen Pharma Grants Stock Options

Vancouver, Canada. November 15, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company exercisable at a price of $1.74 […]

Five Off-road Mobility Devices to Get You Outside in Winter

By Codi Darnell November 15, 2022 It may feel like fall just arrived, but we are one month away from winter. Yes, winter is coming with its shorter days, frigid temperatures, and falling snow. Whether you love it or hate it, if you live in an area of the world that sees the cold and […]

NervGen Pharma Completes Dosing in its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results

Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal females U.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to commence Glenn Ives appointed as Lead Independent Director   […]

When Insurance Says ‘No’

By Codi Darnell November 1, 2022 As a society, we’ve gotten to a place where we have insurance for everything. From homes and vehicles to travel, pets, and health, we take out policies and spend thousands of dollars each year because we believe it means we’re protected. We sleep better at night thinking we are […]

NervGen Engages Cloutier Consulting to Provide Media Relations Services

Vancouver, Canada. October 31, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Cloutier Consulting, a Texas based public relations specialty agency, to provide media relations and related services for the Company. […]

NervGen Pharma Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen’s NVG-291

Dose(s) to be tested in bridging cohorts of males and premenopausal females resulted in significant functional improvements in animal models of nervous system damage NervGen has completed enrollment of third and final multiple ascending dose cohort of postmenopausal women   Vancouver, Canada. October 25, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a […]

NervGen Pharma Presenting at Upcoming Scientific Meetings

AMERICAN NEUROLOGICAL ASSOCIATION ANNUAL MEETING EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS   Vancouver, Canada. October 20, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting posters at two upcoming scientific meetings […]

Navigating New Motherhood in the Aftermath of a Stroke

By Codi Darnell October 18, 2022 Everyone experiences events that alter the course of their life; many of them are embraced: the chance encounters that turn into long-term partnerships; the arrival of a child that transforms you into a parent; the job offer that kickstarts your career. But there are others we hope to avoid […]